Latest News

Image credit: jarun011 | stock.adobe.com
Pirtobrutinib Granted FDA Accelerated Approval for CLL, SLL Based on BRUIN Trial Results

December 4th 2023

Pirtobrutinib (Jaypirca) is a next-generation, highly selected, non-covalent BTK inhibitor that has shown nanomolar potency against wild-type and C481-mutant BTK in cell and enzyme assays.

Image credit: pikovit | stock.adobe.com
Combination of Keytruda Plus Padcev Gets FDA Priority Review for Urothelial Cancer

December 1st 2023

Image credit: SciePro | stock.adobe.com
Promising Trial Data Lead to FDA Fast Track Designation for Breast Cancer Combination Therapy

December 1st 2023

Image credit: Dr_Microbe | stock.adobe.com
FDA Warns of Rare But Serious Reaction to Antiseizure Medications

November 30th 2023

Image credit: intheskies | stock.adobe.com
FDA Grants Orphan Drug Designation to Mocravimod to Improve Outcomes Following Stem Cell Transplantation

November 30th 2023

More News

© 2023 MJH Life Sciences

All rights reserved.